Antithrombotic drugs in acutely ill medical patients: review and meta-analysis of interventional trials with low-molecular-weight heparin and fondaparinux

Author： Loffredo Lorenzo   Perri Ludovica   Catasca Elisa   Del Ben Maria   Angelico Francesco   Violi Francesco  

Publisher： Future Medicine

ISSN： 2044-9038

Source： Clinical Practice, Vol.10, Iss.5, 2013-09, pp. : 615-627

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Comparison between Fondaparinux and Low-Molecular-Weight Heparin in Patients with Acute Coronary Syndrome: A Meta-Analysis

By  

Cardiology, Vol. 133, Iss. 3, 2016-0 ,pp. : 163-172

Karger

Access to resources Recommend Favorite

Low-Molecular-Weight Heparin and Other Antithrombotic Agents in the Setting of a Primarily Medical Treatment of Unstable Coronary Artery Disease

By  

Pathophysiology of Haemostasis and Thrombosis, Vol. 30, Iss. 2, 2004-11 ,pp. : 122-127

Karger

Access to resources Recommend Favorite

Low-Molecular-Weight Heparin and Cancer Survival: Review of the Literature and Pooled Analysis of 1,726 Patients Treated for at Least Three Months

By  

Pathophysiology of Haemostasis and Thrombosis, Vol. 33, Iss. 4, 2004-12 ,pp. : 197-201

Karger

Access to resources Recommend Favorite

Antithrombotic Therapy in Coronary Ischaemia: The Expanding Role of Low-Molecular-Weight Heparin

By  

Pathophysiology of Haemostasis and Thrombosis, Vol. 28, Iss. 3, 2004-11 ,pp. : 35-42

Karger

Access to resources Recommend Favorite

Safety and efficacy of low‐dose fondaparinux (1.5 mg) for the prevention of venous thromboembolism in acutely ill medical patients with renal impairment: the FONDAIR study

By  

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, Vol. 10, Iss. 11, 2012-11 ,pp. : 2291-2297

John Wiley & Sons Inc

Access to resources Recommend Favorite